BioCentury | Jun 15, 2017
Clinical News

NIAID starts Phase I/II of Chikungunya vaccine

...Allergy and Infectious Diseases (NIAID) began a Phase I/II trial of the Chikungunya fever vaccine (MV-CHIKV vaccine...
...180 healthy volunteers. Subjects will receive placebo or 5x10 4 or 5x10 5 TCID50 intramuscular MV-CHIKV vaccine...
...the vaccine next half. Themis Bioscience GmbH , Vienna, Austria Product: Chikungunya fever vaccine , MV-CHIKV vaccine...
BioCentury | Aug 22, 2011
Company News

Inviragen, University of Texas Medical Branch deal

...university granted partner Inviragen exclusive, worldwide rights to a chikungunya virus (CHIKV) vaccine. The recombinant CHIKV vaccine...
Items per page:
1 - 2 of 2